you are viewing a single comment's thread.
The partnership drug with BMY is widely believed to be approved by the FDA on the June 28 PDUFA date three months hence. The upcoming week is the climax to Q1 window-dressing and as one of the Dow's worst performers, I'm expecting weakness out of Pfizer this week.
Pfizer has not been a poor Dow performer this year. So far it has had an effective year to date yield of nearly 2%. Nothing wrong with that.
It is underperforming the S & P by almost ten percentage points. Nothing good about that.Of course, utilizing superior options methods, yours truly is up by 47K or 9.8% on his Pfizer investments so far this year.